Bleomycin-induced pulmonary fibrosis is attenuated by an antibody against KL-6

REFERENCES

• Meltzer EB, Noble PW: Idiopathic pulmonary fibrosis. Or phanet J Rare Dis. 2008;3:8. doi: 10.1186 /1750-1172-3-8.
   PubMed Web of Science ®Google Scholar
• Katzenstein AL, Myers JL: Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med. 1998;157:1301–1315.
   PubMed Web of Science ®Google Scholar
• Katzenstein AL: Pathogenesis of “fibrosis” in interstitial pneumonia: an electron microscopic study. Hum Pathol. 1985;16(10):1015–1024.
   PubMed Web of Science ®Google Scholar
• Kasper M, Haroske G: Alterations in the alveolar epithelium after injury leading to pulmonary fibrosis. Histol Histopathol. 1996;11(2):463–483.
   PubMed Web of Science ®Google Scholar
• Chilosi M, Poletti V, Murer B, Lestani M, Cancellieri A, Montagna L, Piccoli P, Cangi G, Semenzato G, Doglioni C: Abnormal re-epithelialization and lung remodeling in idiopathic pulmonary fibrosis: the role of deltaN-p63. Lab Invest. 2002;82(10):1335–1345.
   PubMed Web of Science ®Google Scholar
• Kohno N, Kyoizumi S, Awaya Y, Fukuhara H, Yamakido M, Akiyama M: New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. Chest, 1989;96(1):68–73.
   PubMed Web of Science ®Google Scholar
• Al-Salmi QA, Walter JN, Colasurdo GN, Sockrider MM, Smith EO, Takahashi H, Fan LL: Serum KL-6 and Surfactant Proteins A and D in Pediatric Interstitial Lung Disease. Chest. 2005;127(1):403–407.
   PubMed Web of Science ®Google Scholar
• Ohnishi H, Yokoyama A, Kondo K, Hamada H, Abe M, Nishimura K, Hiwada K, Kohno N: Comparative Study of KL-6, Surfactant Protein-A, Surfactant Protein-D, and Monocyte Chemoattractant Protein-1 as Serum Markers for Interstitial Lung Diseases. Am J Respir Crit Care Med. 2002;165(3):378–381.
   PubMed Web of Science ®Google Scholar
• Kohno N, Yokoyama A, Hirasawa Y, Kondo K, Fujino S, Abe M, Hiwada K: Comparative studies of circulating KL-6, type III procollagen N-terminal peptide and type IV collagen 7S in patients with interstitial pneumonitis and alveolar pneumonia. Respir Med, 1997;91(9):558–561.
   PubMed Web of Science ®Google Scholar
• Ishii H, Mukae H, Kadota J, Kaida H, Nagata T, Abe K, Matsukura S, Kohno S: High serum concentrations of surfactant protein A in usual interstitial pneumonia compared with non-specific interstitial pneumonia. Thorax, 2003;58(1): 52–57.
   PubMed Web of Science ®Google Scholar
• Goto K, Kodama T, Sekine I, Kakinuma R, Kubota K, Hojo F, Matsumoto T, Ohmatsu H, Ikeda H, Ando M, Nishiwaki Y: Serum levels of KL-6 are useful biomarkers for severe radiation pneumonitis. Lung Cancer, 2001;34(1):141–148.
   PubMed Web of Science ®Google Scholar
• Miyazaki E, Nureki S, Ono E, Ando M, Matsuno O, Fukami T, Ueno T, Kumamoto T: Circulating Thymus- and Activation-Regulated Chemokine/CCL17 Is a Useful Biomarker for Discriminating Acute of Acute Lung Injury Eosinophilic Pneumonia From Other Causes. Chest, 2007;131(6):1726-1734.
   PubMed Web of Science ®Google Scholar
• Sakamoto K, Taniguchi H, Kondoh Y, Johkoh T, Sumikawa H, Kimura T, Nishiyama O, Kato K, Kataoka K, Ono K, Kitaichi M, Hasegawa Y: Serum KL-6 in fibrotic NSIP: Correlations with physiologic and radiologic parameters. Respir Med. 2010;104(1):127-133.
   PubMed Web of Science ®Google Scholar
• Kohno N, Hamada H, Fujioka S, Hiwada K, Yamakido M, Akiyama M: Circulating antigen KL-6 and lactate dehydrogenase for monitoring irradiated patients with lung cancer. Chest, 1992;102(1):117-122.
   PubMed Web of Science ®Google Scholar
• Kobayashi J, Kitamura S: KL-6: a serum marker for interstitial pneumonia. Chest. 1995;108(2):311–315.
   PubMed Web of Science ®Google Scholar
• Iwata Y, Wada T, Furuichi K, Kitagawa K, Kokubo S, Kobayashi M, Sakai N, Yoshimoto K, Shimizu M, Kobayashi K, Yokoyama H: Serum Levels of KL-6 Reflect Disease Activity of Interstitial. patients with ANCA-related vasculitis. Intern Med, 2001;40(11):1093-1097.
   PubMed Web of Science ®Google Scholar
• Yokoyama A, Kohno N, Hamada H, Sakatani M, Ueda E, Kondo K, Hirasawa Y, Hiwada K: Circulating KL-6 Predicts the Outcome of Rapidly Progressive Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med, 1998;158(5 Pt 1): 1680–1684.
   PubMed Web of Science ®Google Scholar
• Satoh H, Kurishima K, Ishikawa H, Ohtsuka M: Increased levels of KL-6 and subsequent mortality in patients with interstitial lung diseases. J Intern Med, 2006;260(5):429–434.
   PubMed Web of Science ®Google Scholar
• Ashcroft T, Simpson JM, Timbrell V: Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol. 1988;41(4):467–470.
   PubMed Web of Science ®Google Scholar
• Hirasawa Y, Kohno N, Yokoyama A, Inoue Y, Abe M, Hiwada K: KL-6, a Human MUC1 Mucin, Is Chemotactic for Human Fibroblasts. Am J Respir Cell Mol Biol. 1997;17(4): 501–507.
   PubMed Web of Science ®Google Scholar
• Ohshimo S, Yokoyama A, Hattori N, Ishikawa N, Hirasawa Y, Kohno N: KL-6, a human MUC1 mucin, promotes proliferation and survival of lung fibroblasts. Biochem Biophys Res Commun. 2005;338(4):1845–1852.
   PubMed Web of Science ®Google Scholar
• Moore BB, Hogaboam CM: Murine models of pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2008;294(2):L152–L160.
   PubMed Web of Science ®Google Scholar
• Oury TD, Thakker K, Menache M, Chang LY, Crapo JD, Day BJ: Attenuation of bleomycin-induced pulmonary fibrosis by a catalytic antioxidant metalloporphyrin. Am J Respir Cell Mol Biol. 2001;25(2):164–169.
   PubMed Web of Science ®Google Scholar
• Bergeron A, Soler P, Kambouchner M, Loiseau P, Milleron B, Valeyre D, Hance AJ, Tazi A: Cytokine profiles in idiopathic pulmonary fibrosis suggest an important role for TGF-beta and IL-10. Eur Respir J. 2003;22(1):69–76.
   PubMed Web of Science ®Google Scholar
• Khalil N, O'Connor RN, Flanders KC, Unruh H: TGF-beta 1, but not TGF-beta 2 or TGF-beta 3, is differentially present in epithelial cells of advanced pulmonary fibrosis: An immunohistochemical study. Am J Respir Cell Mol Biol. 1996;14(2):131–138.
   PubMed Web of Science ®Google Scholar
• Gharaee-Kermani M, Phan SH: Molecular mechanisms of and possible treatment strategies for idiopathic pulmonary fibrosis. Curr Pharm Des. 2005;11(30):3943–3971.
   PubMed Web of Science ®Google Scholar
• Krishna G, Liu K, Shigemitsu H, Gao M, Raffin TA, Rosen GD: PG490-88, a derivative of triptolide, blocks bleomycin-induced lung fibrosis. Am J Pathol. 2001;158(3): 997–1004.
   PubMed Web of Science ®Google Scholar
• Sime PJ, Xing Z, Graham FL, Csaky KG, Gauldie J: Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung. Clin Invest. 1997;100(4):768-776.
   Google Scholar
• Marchand-Adam S, Marchal J, Cohen M, Soler P, Gerard B, Castier Y, Lesèche G, Valeyre D, Mal H, Aubier M, Dehoux M, Crestani B: Defect of Hepatocyte Growth Factor Secretion by Fibroblasts in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2003;168(10):1156–1161.
   PubMed Web of Science ®Google Scholar
• Marchand-Adam S, Fabre A, Mailleux AA, Marchal J, Quesnel C, Kataoka H, Aubier M, Dehoux M, Soler P, Crestani B: Defect of Pro-Hepatocyte Growth Factor Activation by Fibroblasts in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2006;174(1):58–66.
   PubMed Web of Science ®Google Scholar